Cite

Figure 1

Kaplan-Meier estimate of loco-regional failure free survival (LRFFS).
Kaplan-Meier estimate of loco-regional failure free survival (LRFFS).

Figure 2

Kaplan-Meier estimate of distant metastasis free survival (DMFS).
Kaplan-Meier estimate of distant metastasis free survival (DMFS).

Figure 3

Kaplan-Meier estimate of overall survival (OS).
Kaplan-Meier estimate of overall survival (OS).

Patient and treatment characteristics

Characteristics ValuesN=100N (%)
Gender
 Female 38 (38%)
 Male 62 (62%)
 Histological subtype
 Keratinizing 2 (2%)
 Non-keratinizing; differentiated 32 (32%)
 Non-keratinizing; undifferentiated 66 (66%)
Stage
 II 23 (23%)
 III 45 (45%)
 IVA 21 (21%)
 IVB 11 (11%)
T stage
 T1 28 (28%)
 T2 30 (30%)
 T3 20 (20%)
 T4 22 (22%)
N stage
 N0 5 (5%)
 N1 30 (30%)
 N2 54 (54%)
 N3a 7 (7%)
 N3b 4 (4%)
Dose statistic
 D95% of PTV70, mean (SD) 70.2 (0.5)
 D95% of PTV59.4, mean (SD) 59.8 (0.6)
 D95% of PTV54, mean (SD) 54.3 (0.8)
 Conformity index (CI), mean (SD) 0.89 (0.13)
 Homogeneity index (HI), mean (SD) 0.06 (0.07)
 D2% of spinal cord, median (SD) 34.1 (4.4)
 D2 cc of brainstem, mean (SD) 53.3 (6.3)
 D50 of ipsilateral parotid gland, mean (SD) 38.5 (11.2)
 D50 of contralateral parotid gland, mean (SD) 28.4 (6.7)

Comparative studies of outcome and toxicities in NPC treated by HT concurrent with chemotherapy

Study Median Follow up (Range) (month) No. of CCRT (%) LRFFS (%) DMFS (%) OS (%) Severe toxicity (grade > 2)

Acute Dermatitis (%) Acute Mucositis (%) Acute Pharyngitis (%) Acute Xerostomia (%) Late Xerostomia (%)
Wong et al. 22 34 (9-50) 70 93.6 (3 yr) 86.6 (3 yr) 87.2 (3 yr) - 67.4 - - 2.3
Wolden et al. 23 35 (3-74) 93 91 (3 yr) 78 (3 yr) - - - - - -
Kam et al. 24 29 (8-45) 30 92 (3 yr) 79 (3 yr) 90 (3 yr) - 92 - 75 23 (2 yr)
Lee et al. 7 31 (6-55) 65 89.3 (2 yr) 84.7 (2 yr) 80.2 (2 yr) - 4.4 (grade4) - - 3.1
Tham et al. 25 36.5 100 93.1 (3 yr) - - - 29 - 3 -
Lee et al. 26 31 (7-22) 75 98 (4 yr) 66 (4 yr) 88 (4 yr) - 94 - - 2.5 ( 2 yr)
Liu et al. 27 13 (8/18) 58 100 (13 M) - - 5 79 - 5 -
Wang et al. 28 47.1 (11-68) 83 94 (4 yr) 85 (4 yr) 86.1 (4 yr) - 33.3 - 4.7 12.3 (2 yr)
Sultanem et al. 27 21.8 (5-49) 91 100 (4 yr) 57 (4 yr) 94 (4 yr) - 51 (grade3) - - -
Du et al. 20 32 (3-38) 64 96.1 (3 yr) 92 (3 yr) 86.3 (3 yr) 4.7 3.2 - 0 -
Leung et al. 17 41 (0.2-67) 62.5 97 (5 yr) 84.6 (5 yr) - 0 4 - - 0
Du et al. 21 23.7 (12-38) 100 92.2 (2 yr) 92.7 (2 yr) 93.2 (2 yr) 5.3 9.1 0.5 (grade 3) 0 -
Zhang et al. 30 48 (41.7-58) 100 (cetuximab) 95.2 (2 yr) 88.1 (2 yr) 93 (2 yr) 7 (grade3) 81.4 (grade3) - - -
Our Study 33 (25-41) 100 94 (2 yr) 96 (2 yr) 99 (2 yr) 5 37 (grade3) 51 (grade 3) - 5 (grade 3)
eISSN:
1581-3207
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology